反应详情

The aforesaid tert-butyl N-[(3S)-1-[6-[6-(5-isopropyl-3-pyridyl)pyrazolo[4,3-c]pyridin-1-yl]-2-pyridyl]-3-piperidyl]carbamate in DCM (5 mL) and TFA (5 mL) was stirred at room temperature for 1 h. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford 108 (33.9 mg, 37%). 1H NMR (400 MHz, DMSO) δ 9.35-9.30 (s, 1H), 9.13-9.10 (d, J=2.0 Hz, 1H), 9.06-9.02 (s, 1H), 8.66-8.61 (s, 1H), 8.58-8.55 (d, J=2.0 Hz, 1H), 8.35-8.31 (d, J=1.9 Hz, 1H), 7.78-7.70 (t, J=8.1 Hz, 1H), 7.23-7.17 (d, J=7.7 Hz, 1H), 6.84-6.78 (d, J=8.5 Hz, 1H), 4.32-4.14 (dd, J=37.4, 11.8 Hz, 2H), 3.12-3.01 (td, J=12.8, 5.7 Hz, 2H), 2.87-2.70 (ddd, J=15.5, 13.1, 7.6 Hz, 2H), 1.96-1.74 (m, 2H), 1.64-1.51 (dd, J=24.5, 11.5 Hz, 2H), 1.33-1.31 (d, J=7.0 Hz, 6H); MS (ESI) m/z: 414.1 [M+H]+

1. concentrationThe mixture was concentrated
2. customthe residue was purified by reverse phase HPLC